Leukaemia
What every doctor should know about CLL in today’s treatment landscape
QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD
MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib
Long-term success for CD19 CAR T-cell therapy in CLL
Next-generation cell therapies for cancer: CAR-NK cells
Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT
Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT
Is ASCT a reasonable option in patients with invasive aspergillosis?
Tacrolimus versus cyclosporine A in AML
Promising novel target identified for AML
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL
Ibrutinib plus venetoclax displays long-term benefits in CLL
Excellent results for triplet regimen in FLT3-mutated AML
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML
Promising results for triplet therapy with magrolimab in AML
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL
High-dose methotrexate or standard interim maintenance in young patients with ALL?
Real world outcomes show ibrutinib delays need for next treatment longer than acalabrutinib in first-line CLL
Should we use intensive chemotherapy prior to allo-HCT in rel/ref AML?
Pan-clonal score predicts first-line treatment response in AML
Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML
No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics
New subtypes of oncogenic deregulation in childhood T-ALL
Triple-therapy improves PFS in fit, previously untreated CLL
Young leukemia survivors face higher-than-average mortality rates for decades
Inhibiting the LSD1 enzyme renders some leukemia cells sensitive to TKI treatment
Adding ivosidenib to azacitidine improves survival in IDH1-mutated AML
Newly characterized mutation may define a novel leukemia subtype in kids
New Interfant protocol includes blinatumomab for KMT2A-r ALL
Persistent disparities in ALL health outcomes
EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL
UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL
AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML
Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients
Promising frontline triplet regimen for TP53-mutated AML
Encouraging results of novel triplet combination for AML
Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML
Improved risk stratification in MDS via gene-based scoring system
CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL
SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL
Investigational therapies superior to standard-of-care in double-exposed CLL
Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms
Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL
Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
CAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL
Limited evidence supports many hematopoietic stem cell transplant guidelines
Acalabrutinib on par with ibrutinib, easier to tolerate in advanced CLL
Olutasidenib demonstrates efficacy in patients with relapsed/refractory IDH1 mutant AML
Acalabrutinib as effective but better tolerated than ibrutinib in CLL
Stop vincristine-dexamethasone pulse therapy in low-risk childhood ALL after one year: trial
ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety compared with ibrutinib
ELEVATE-TN: Long-term efficacy in chronic lymphocytic leukemia
Sabatolimab achieved durable responses in patients with high-risk MDS and AML
Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia
Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL
Oral azacitidine improves overall survival in patients with acute myeloid leukaemia
Reduced-intensity conditioning ASCT is effective in older patients with AML
ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia
ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib
Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL
GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment
Protein profiles may predict stable, progressive chronic lymphocytic leukemia
Whole-genome sequencing identifies more gene defects in patients with blood cancer
More complicated course of COVID-19 in leukaemia patients
Older age and imatinib treatment associated with COVID-19 mortality in CML
Improved outcomes, but still substantial part experiences relapses
Strong correlation between peripheral blood and bone marrow NGS MRD
Encouraging outcomes after autoHCT in patients with ALL
Prognostic validity of AML composite model in predicting mortality
Venetoclax plus hypomethylating agents in favourable-risk AML
Encouraging clinical activity of decitabine plus ipilimumab in R/R or secondary MDS/AML
Bosutinib effective and well tolerated in newly diagnosed CP-CML
AML patients with specific mutations are unlikely to achieve MRD
Comparable outcomes with gilteritinib or quizartinib in R/R AML
First-in-class macrophage immune checkpoint inhibitor in AML
Bispecific DART® as salvage therapy for primary induction failure and early relapse
Efficacy and safety of ponatinib in patients with CP-CML who failed second-generation TKIs
Gilteritinib in R/R AML patients priorly treated with midostaurin or sorafenib
Addition of venetoclax provides an effective, lower-intensity regimen
First-in-class STAMP inhibitor versus bosutinib in resistant or intolerant CML
PFS and ORR benefits of first-line ibrutinib-based treatment in CLL
PARP inhibitors linked to myelodysplastic syndrome, AML, meta-analysis confirms
Origins of blood cancer traced to early childhood, decades before diagnosis
New guideline helps patients and parents navigate pediatric acute lymphoblastic leukemia
OS benefit in VIALE-C trial
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Two trials: acalabrutinib in CLL
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Venetoclax + navitoclax promising for R/R ALL or LL
Microbiome predicts B-ALL predisposition
Socioeconomic disparities and survival in paediatric AML
Likely new standard of care: Blinatumomab for children with relapsed B-ALL
Oral azacitidine improves overall survival in patients with AML in remission
Mild renal impairment in African Americans does not affect OS in AML
Anti-CD70 is safe with hypomethylating agents in AML
20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon
MRD assessment to guide pre-emptive treatment decisions
Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT
Residual disease in AML patients prior to stem cell transplant increases relapse risk
Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL
Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML
CAR-T cell therapy in ALL as breakthrough advance
Initial data on AMV564 in patients with relapsed/refractory AML
Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL
ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL
Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia
